

Conflict of Interest Disclosure Instructions

Please complete one for every investigator on your application.

Disclosure Statement

SRS must ensure balance, independence, objectivity and scientific rigor in all educational activities. Therefore, any person who is in a position to influence or control the content of a CME activity must disclose ALL RELEVANT financial relationships with any commercial interest* producing healthcare goods or services. A financial relationship may include such things as grants or research support, employee, consultant, major stockholder, member of speaker's bureau, etc. that has occurred for any dollar amount over the past 12 months. The intent of disclosure is not to prevent a speaker with a financial or other relationship from making a presentation, but rather to resolve any conflicts prior to the CME activity so the learner may participate in a balanced, unbiased CME event.

Items to be disclosed should include:

1. Any remuneration from a company*, including but not limited to salary, stock ownership, stock options, stock warrants, royalties, consulting fees, loans and honoraria or reimbursement for speaking; and
2. Any gifts from a company, including but not limited to endowments, sponsorship of trips, support of training (such as fellowships) and other sponsorships; and
3. Company support for research, including but not limited to equipment, biomaterials, discretionary funds, support of office or research staff; and
4. Holding office in a company, including but not limited to positions on the board of directors or scientific advisory board.

*For purposes of this document, "Commercial Interest" and "Company" shall be defined as any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients.

Any deliberate failure to disclose relationships and other actions related to maintenance of full disclosure and COI can lead to disciplinary action or warning.

Please ONLY disclose relationships with commercial interests

Guidelines Regarding Commercial Support and Disclosure

Disclosure

- Speakers/authors/planning committee members/content reviewers/staff must complete and submit the disclosure statement to their involvement in planning or presenting/authoring a CME activity.
- Speakers/authors/planning committee members/content reviewers/staff are required to disclose all relevant and financial relationships that they have with a commercial interest that have occurred in the previous 12 months.

Content Validation

- Speakers/authors are required to prepare fair and balanced presentations that are objective and scientifically rigorous. All clinical recommendations must be based on evidence accepted within the medical profession as adequate justification for their indications and contraindications in the care of patients. All scientific research referred to, reported, or used to support a patient care recommendation must conform to generally accepted standards of experimental design, data collection and analysis.

Unlabeled and Unapproved Uses

- Presentations that provide information in whole or in part related to non FDA approved uses of drugs and/or devices must clearly disclose the unlabeled indications or the investigational nature of their proposed uses to the audience. Please document in the abstract FDA disclosure.

Use of Generic vs. Trade Names

- The SRS Board of Directors has determined that the term hardware should not be used in written abstract submissions, oral presentations and E-Poster presentations. The terms instrumentation, implants, or constructs, should be used instead.
- SRS strongly prefers that pharmaceuticals and proprietary software/databases as well as surgical approaches or specific instrumentation such as “Surgimap, MIMICS, EOS Imaging, RHOTEM, Isola, TSRH, CD, XLIF, DLIF, AxiaLIF, Solera, Vertex, Expedium, Mountaineer, Shilla, VEPTR etc.,” are not used in an abstract. These terms should be replaced by a generic term or description of the drug, software/database and/or instrumentation or technique unless the use of the term directly impacts learners’ understanding of the presentation or data. Instrumentation may also be referred to when the device name is a landmark system that is no longer sold (i.e. Harrington, Cotrel-Dubousset, Luque). Company names and logos must never be used in a presentation.
- It is recognized that studies evaluating a product or products or comparing different products or techniques may require the use of product or technique names. If a product trade name or industry developed technique using a trademarked name are used in an abstract or presentation, the author must disclose their intent to use the term at the time of abstract submission and the abstract will be specifically reviewed by the CME Committee for evaluation of any potential conflict of interest. When there is a known potential conflict of interest, an expanded verbal disclosure will be necessary at the time of presentation. Furthermore, if a product name is mentioned, the audience should be informed of why it is necessary to give the name.

Commercial Supporter Influence

- No payments or gifts after the SRS honoraria policy may be given by a commercial interest to the director of the activity, planning committee members, teachers or authors, joint provider, or any others involved with the CME activity receiving commercial support.
- Speakers/authors should not receive or accept direct input from a commercial interest regarding the content or in the preparation of the presentation(s).